A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: stagelymphomacellriskintermediate
  Phrases that lowered it: nasalevaluate thesingleto evaluatetrial
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 4 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 18.8% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 26 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Maximum age: 70 (lowers risk) · Who can join
• Drug's FAERS reports before start: 95920 (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 96.7% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 10481 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drugs with FDA adverse-event history: 5 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 6 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial NCT04602065 · started 2020 · scored riskier than 82% of active trials terminated
• Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma NCT02276248 · started 2010 · scored riskier than 52% of active trials completed
• P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens NCT02533323 · started 2012 · scored riskier than 27% of active trials terminated
• Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage NCT02359162 · started 2015 · scored riskier than 17% of active trials terminated
• Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma NCT04004572 · started 2019 · scored riskier than 43% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.